Profound Medical Corp (PROF) Stock Price, Quote & News

Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or phys...

Industry: Medical Devices

Sector: Healthcare

Phone: 647 476 1350

Fax: 647 847 3739

Website: www.profoundmedical.com

Address:

2400 Skymark Avenue, Unit 6, Mississauga, Canada

BioTuesdays Oct. 16 at 1:59 PM

$PROF has unveiled new, real-world data from the internationally recognized Busch Center—marking the completion of 500 TULSA Procedures. This milestone highlights the versatility and success in treating a broad spectrum of prostate diseases, severities, and aggressions using a unique incision-free, MRI-guided approach https://biotuesdays.com/2025/10/16/profound-congratulates-busch-center-for-500th-tulsa-procedure-achieved/

0 · Reply

healthcareguru Oct. 10 at 2:01 PM

$PROF Imminent Bankruptcy…or >50% Dilution. Pick your poison bc they are OUT OF CASH NOW. 🐺👎 $XBI $XLV $IWM $IHI

2 · Reply

OnTheBalance Oct. 9 at 3:13 PM

$PROF upwards

0 · Reply

Snowlo Oct. 8 at 7:37 PM

$PROF Took a starter position of 500 shares and 5 call options into 2026. This could 100x on the slightest bit of a breakthrough... which seems imminent.

0 · Reply

BioTuesdays Oct. 7 at 4:50 PM

$PROF announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of between 84% and 87%. This compares favorably to consensus analyst estimates of $4.7 million in revenue for the quarter https://biotuesdays.com/2025/10/07/profound-sees-record-revenues-in-q3-2025-up-84-87-yoy-with-higher-gross-margin/

0 · Reply

OnTheBalance Oct. 7 at 1:29 PM

$PROF accumulators always post BS to assist their accumulation

0 · Reply

healthcareguru Oct. 7 at 12:41 PM

$PROF you guys release they’re going to miss every single Street estimate, right? Whiff on sales rest of year and guide a mile below for 2026… 👎

1 · Reply

OnTheBalance Oct. 6 at 8:23 PM

$PROF Upwards WSJ has 5 analysts on this stock, 4 BUYS, 1 Overweight.

0 · Reply

NVDAMillionaire Sep. 29 at 3:52 PM

$PROF Outstanding article that hits the mark on PROF's current state. So if you want to refresh your PROF insights or learn about PROF from scratch, this is a must read. https://beyondspx.com/quote/PROF/analysis/profound-medical-s-precision-ablation-ignites-mainstream-prostate-care-expansion-nasdaq-prof

2 · Reply

StockScanners Sep. 25 at 1:26 AM

$PROF reached 5.56

0 · Reply

Profound Medical to Participate in the Stifel 2025 Healthcare Conference

Oct 7, 2025, 7:45 AM EDT - 19 days ago

Profound Medical Achieves Record Preliminary Unaudited Revenue for the 2025 Third Quarter

Sep 23, 2025, 8:00 AM EDT - 4 weeks ago

Texas Prostate and Dallas Medical Center Launch First-of-its-Kind TULSA Program, Expanding Access to Advanced Prostate Treatment

Aug 28, 2025, 8:00 AM EDT - 2 months ago

Profound Medical to Participate in Lake Street's 9th Annual Best Ideas Growth Conference

Aug 18, 2025, 7:01 PM EDT - 2 months ago

Profound Medical: Smokes Is Everywhere, Initiate At Sell

Aug 14, 2025, 9:24 PM EDT - 2 months ago

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

PRN

Aug 14, 2025, 4:05 PM EDT - 2 months ago

Profound Medical Announces Second Quarter 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 3 months ago

Profound Medical to Release Second Quarter 2025 Financial Results on August 14 – Conference Call to Follow

May 14, 2025, 4:45 PM EDT - 5 months ago

Profound Medical Annual General and Special Meeting of Shareholders Voting Results

May 9, 2025, 7:17 AM EDT - 6 months ago

Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

Apr 30, 2025, 4:30 PM EDT - 6 months ago

Profound Medical to Participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference

Apr 29, 2025, 7:30 AM EDT - 6 months ago

Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy

Apr 15, 2025, 7:45 AM EDT - 6 months ago

Profound Medical AUA 2025 Investor Event Agenda

Apr 8, 2025, 10:00 AM EDT - 7 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Apr 8, 2025, 9:32 AM EDT - 7 months ago

PROF Investors Have Opportunity to Join Profound Medical Corp. Fraud Investigation with the Schall Law Firm

Apr 7, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Shareholders to Inquire about Securities Investigation

Apr 6, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Shareholders to Connect

Apr 4, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Shareholders to Reach Out

Apr 3, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Investors to Learn More About the Investigation

Apr 2, 2025, 10:00 AM EDT - 7 months ago

Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Apr 1, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Investors to Connect

Mar 31, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Stockholders to Inquire about Securities Investigation

Mar 28, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Profound Medical Corp. (PROF) and Encourages Stockholders to Learn More About the Investigation

Mar 27, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Profound Medical Corp. (PROF) Investors to Inquire about Securities Investigation

Mar 26, 2025, 9:59 PM EDT - 7 months ago

Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws

Mar 26, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Investors to Reach Out

Mar 25, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Profound Medical Corp. (PROF) And Encourages Stockholders to Reach Out

Mar 24, 2025, 1:00 PM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Profound Medical Corp. (PROF) And Encourages Stockholders to Connect

Mar 6, 2025, 8:35 PM EST - 8 months ago

Profound Medical Corporation (PROF) Q4 2024 Earnings Conference Call Transcript

Feb 13, 2025, 5:00 PM EST - 9 months ago

Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow

Jan 8, 2025, 7:30 AM EST - 10 months ago

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues

Jan 6, 2025, 8:15 AM EST - 10 months ago

Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 10, 2024, 9:55 AM EST - 11 months ago

Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares

Dec 6, 2024, 9:04 AM EST - 11 months ago

Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares

Dec 5, 2024, 4:48 PM EST - 11 months ago

Profound Medical Announces Proposed Public Offering of Common Shares

Dec 2, 2024, 7:30 AM EST - 11 months ago

Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy

Nov 26, 2024, 7:45 AM EST - 11 months ago

Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant'

Nov 10, 2024, 8:50 AM EST - 1 year ago

Profound Medical Corporation (PROF) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 6:55 AM EST - 1 year ago

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Oct 17, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer

Sep 4, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Participate in Lake Street's Best Ideas Growth Conference

Aug 8, 2024, 11:11 PM EDT - 1 year ago

Profound Medical Corporation (PROF) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:30 PM EDT - 1 year ago

Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Profound Medical Announces Category 1 CPT Codes Proposed CY2025 Rule for TULSA to Treat Prostate Diseases

May 15, 2024, 5:00 PM EDT - 1 year ago

Profound Medical Annual General Meeting of Shareholders Voting Results

BioTuesdays Oct. 16 at 1:59 PM

0 · Reply

healthcareguru Oct. 10 at 2:01 PM

$PROF Imminent Bankruptcy…or >50% Dilution. Pick your poison bc they are OUT OF CASH NOW. 🐺👎 $XBI $XLV $IWM $IHI

2 · Reply

OnTheBalance Oct. 9 at 3:13 PM

$PROF upwards

0 · Reply

Snowlo Oct. 8 at 7:37 PM

$PROF Took a starter position of 500 shares and 5 call options into 2026. This could 100x on the slightest bit of a breakthrough... which seems imminent.

0 · Reply

BioTuesdays Oct. 7 at 4:50 PM

0 · Reply

OnTheBalance Oct. 7 at 1:29 PM

$PROF accumulators always post BS to assist their accumulation

0 · Reply

healthcareguru Oct. 7 at 12:41 PM

$PROF you guys release they’re going to miss every single Street estimate, right? Whiff on sales rest of year and guide a mile below for 2026… 👎

1 · Reply

OnTheBalance Oct. 6 at 8:23 PM

$PROF Upwards WSJ has 5 analysts on this stock, 4 BUYS, 1 Overweight.

0 · Reply

NVDAMillionaire Sep. 29 at 3:52 PM

2 · Reply

StockScanners Sep. 25 at 1:26 AM

$PROF reached 5.56

0 · Reply

StockScanners Sep. 24 at 1:37 AM

$PROF keep watch if this holds above 4.85

0 · Reply

FinancialScience Sep. 23 at 11:57 PM

$PROF https://texasprostate.com/sumbul-shaikh/

0 · Reply

DSWN Sep. 23 at 11:03 PM

$PROF On a technical side , five year trend channel resistance at $9.10. Then Fibo at 11.91 Let’s just say, I hope we blow through that

0 · Reply

QES Sep. 23 at 1:24 PM

$PROF The program is notable for several reasons: It specifically enables Medicare-covered patients to receive the TULSA procedure for both prostate cancer and benign prostatic hyperplasia (BPH) Same-day, minimally invasive treatment with no overnight hospital stay, no procedural blood loss, and a significantly lower risk of side effects like incontinence or erectile dysfunction compared to traditional surgery It demonstrates a novel business model where a private urology practice collaborates with a hospital to deliver this advanced treatment, creating a template that could be replicated nationwide to improve access to state-of-the-art prostate care for Medicare patients.

0 · Reply

RFL2 Sep. 22 at 10:31 PM

$PROF anyone have an idea about why the incredibly high volume today? Didn't help the stock but maybe it put in the bottom

2 · Reply

johntarlick Sep. 21 at 1:28 PM

$PROF well i was curious if any of the insiders had bought on the recent dip, as they had done on the similar dip back in the spring. Turns out 3 of the 4 did so again this time, but one did not and that one was, unexpectedly, the CCO. The guy who is under the gun to deliver the goods, right here, right now. And who has strongly asserted he's got dozens of virtually complete sales that will finalize before 2026. One good quarterly report, which will also be the first ever good quarterly report, ought to blow the lid off the stock price and that dip was a golden buying opportunity.

2 · Reply

Bigskies Sep. 20 at 6:53 PM

$PROF This is the time for management to step up and grow the business. I trust that they are getting the equipment installed and promoting its use. Nothing holding them back.

0 · Reply

johntarlick Sep. 12 at 2:02 PM

$PROF hmmm not sure what just happened this week, another lurch. I hesitate to table this, and it's usually just background noise, but the reviews over on glassdoor have recently taken a similar lurch. Sour grapes is one thing, but there is a theme that shows consistently through on almost every single review, and that is, it's great technology. Everyone that has worked on it, has understood it and has liked it.

0 · Reply

RFL2 Aug. 24 at 8:15 PM

$PROF the real drawback they don't talk about is a catheter for about a week. Am I wrong?

2 · Reply

SmartMoneyTradez Aug. 19 at 2:26 AM

$WALD $PROF

0 · Reply

johntarlick Aug. 17 at 1:10 PM

$PROF I'm inclined to give the benefit of the doubt on the pipeline. After all, management has been asked about the new installs 'pipeline' on just about every call for some years now, and has NEVER agreed to say what it was. In sharp contrast to that, the pipeline was here delivered as a veritable cold open. So I can't imagine those numbers aren't to some extent true. What really concerned me, is that the recurring revenue was up only 7% quarter over quarter. Aside from any issues on the pipeline, there are 60 installed sites and those sites need to be growing their business by more than 7% per year. What happened? None of the analysts asked.

1 · Reply

mlanthoo Aug. 16 at 3:28 PM

$PROF it seems this management team overpromises and underdelivers on an ongoing basis . time for new direction as current management isn't getting the job done . always an excuse .

0 · Reply

Market Cap	166.07M
Revenue (ttm)	10.68M
Net Income (ttm)	-27.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-260.49%
Debt to Equity Ratio	0.11

Volume	102,000
Avg Vol	152,506
Day's Range	N/A - N/A
Shares Out	30.19M
Stochastic %K	37%
Beta	0.66
Analysts	Strong Sell
Price Target	$12.31